Association between interleukin-18 gene promoter (-607C/A and -137G/C) polymorphisms and chronic hepatitis C virus infections: A meta-analysis

Meta Gene

Volumn 5, Issue , 2015, Pages 21-31

  Yang, Yi ^a   Liu, Hao ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

HCV; Hepatitis C virus; IL 18; Interleukin 18; Meta analysis; Polymorphism

Indexed keywords

ARTICLE; CHRONIC HEPATITIS C; DATA EXTRACTION; GENE; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTERLEUKIN 18 GENE; PRIORITY JOURNAL; PROMOTER REGION; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS;

HEPATITIS C VIRUS;

EID: 84929994169     PISSN: None     EISSN: 22145400     Source Type: Journal    
DOI: 10.1016/j.mgene.2015.04.004     Document Type: Article

References (39)

1. An P., Thio C.L., Kirk G.D., Donfield S., Goedert J.J., Winkler C.A. Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance. J. Infect. Dis. 2008, 198(8):1159-1165.
2. Averhoff F.M., Glass N., Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin. Infect. Dis. 2012, 55:S10-S15.
3. Bouzgarrou N., Hassen E., Schvoerer E., et al. Association of interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection. J. Med. Virol. 2008, 80(4):607-614.
4. Cannings C., Edwards A.W. Expected genotypic frequencies in a small sample: deviation from Hardy-Weinberg equilibrium. Am. J. Hum. Genet. 1969, 21(3):245-247.
5. Chikano S., Sawada K., Shimoyama T., et al. IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-gamma dependent manner. Gut 2000, 47(6):779-786.
6. Choi J., Ou J.H.J. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. American Journal of Physiology-Gastrointestinal And Liver Physiology 2006, 290(5):G847-G51.
7. Dao T., Ohashi K., Kayano T., Kurimoto M., Okamura H. Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell. Immunol. 1996, 173(2):230-235.
8. Davis K.L., Mitra D., Medjedovic J., Beam C., Rustgi V. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J. Clin. Gastroenterol. 2011, 45(2):E17-E24.
9. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin. 1986, 7:177-188.
10. Dinarello C.A. Interleukin-18, a proinflammatory cytokine. Eur. Cytokine Netw. 2000, 11(3):483-486.
11. Fassio E. Hepatitis C and hepatocellular carcinoma. Ann. Hepatol. 2010, 9:S119-S122.
12. Haas S.L., Weiss C., Bugert P., et al. Interleukin 18 promoter variants (-137G>C and -607C>A) in patients with chronic hepatitis C: association with treatment response. J. Clin. Immunol. 2009, 29(5):620-628.
13. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21:1539-1558.
14. Hindorff L.A., Sethupathy P., Junkins H.A., et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(23):9362-9367.
15. Imran M., Manzoor S., Parvaiz F. Predictive potential of IL-18 -607 and osteopontin -442 polymorphism in interferon-based therapy of HCV infection in the Pakistani population. Viral Immunol. 2014, 27(8):404-411.
16. Ioannidis J.P. Genetic associations: false or true?. Trends Mol. Med. 2003, 9(4):135-138.
17. Ioannidis J.P., Trikalinos T.A., Khoury M.J. Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am. J. Epidemiol. 2006, 164(7):609-614.
18. Jackson D., White I.R., Riley R.D. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat. Med. 2012, 31:3805-3820.
19. Jhaveri R., Grant W., Kauf T.L., McHutchison J. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. J. Pediatr. 2006, 148(3):353-358.
20. Lauer G.M., Walker B.D. Medical progress: hepatitis C virus infection. N. Engl. J. Med. 2001, 345(1):41-52.
21. Mandour M., Nemr N., Kishk R., Ahmed E. Impact of the IL-18 gene polymorphism in response to antiviral therapy in chronic HCV genotype 4 patients. Rev. Soc. Bras. Med. Trop. 2014, 47(2):137-142.
22. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22:719-748.
23. McGuinness P.H., Painter D., Davies S., McCaughan G.W. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut 2000, 46(2):260-269.
24. McHutchison J.G., Bacon B.R. Chronic hepatitis C: an age wave of disease burden. Am. J. Manag. Care 2005, 11(10):S286-S295.
25. Niederau C., Lange S., Heintges T., et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology (Baltimore, Md) 1998, 28(6):1687-1695.
26. Peano G., Menardi G., Ponzetto A., Fenoglio L.M. HLA-DR5 antigen. A genetic factor influencing the outcome of hepatitis C virus infection?. Arch. Intern. Med. 1994, 154(23):2733-2736.
27. Peters J.L.A.J.Sutton, Jones D.R., Abrams K.R., Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006, 295(6):676-680.
28. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997, 349(9055):825-832.
29. Rauch A., Kutalik Z., Descombes P., et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138(4):1338-U173.
30. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J. Clin. Investig. 2009, 119(7):1745-1754.
31. Sharma A., Chakraborti A., Das A., Dhiman R.K., Chawla Y. Elevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesis. Immunology 2009, 128(1):e514-e522.
32. Shepard C.W., Finelli L., Alter M. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005, 5(9):558-567.
33. Stadhouders P., Cooreman M.P. Chronic hepatitis C virus disease: an evaluation of procedures for diagnosis and treatment. Neth. J. Med. 1997, 51(6):213-224.
34. Thomas D.L., Astemborski J., Rai R.M., et al. The natural history of hepatitis C virus infection - host, viral, and environmental factors. JAMA 2000, 284(4):450-456.
35. Thursz M., Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat. Rev. Gastroenterol. Hepatol. 2014, 11(1):28-35.
36. Tsutsui H., Matsui K., Kawada N., et al. IL-18 accounts for both TNF-alpha- and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J. Immunol. 1997, 159(8):3961-3967.
37. WHO Consulatation Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral Hepat. 1999, 6:35-47.
38. Wong J.B., McQuillan G.M., McHutchison J.G., Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am. J. Public Health 2000, 90(10):1562-1569.
39. Zeremski M., Petrovic L.M., Talal A.H. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J. Viral Hepat. 2007, 14(10):675-687.